|Day's Range||1,430.00 - 1,450.00|
|52 Week Range||970.00 - 1,489.00|
|PE Ratio (TTM)||73.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Q1 2017 Genmab A/S Earnings Call
Q4 2016 Genmab A/S Earnings Call
Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday. The $1 billion a year required to achieve blockbuster is now in sight, with net sales of Darzalex -- approved in November 2015 and is marketed by Johnson & Johnson (J&J) -- expected to reach between $1.1 billion and $1.3 billion this year, up from $572 million in 2016, Genmab said. Genmab receives tiered royalties from J&J on its sales and expects to receive Darzalex royalties of between 930 million Danish crowns and 1,100 million crowns ($132 million-$156 million) and 800 million crowns in milestone payments this year.